Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline in Neonates With Hypoxic Ischemic Encephalopathy
NCT06522581Phase 1Recruiting
- Sponsor
- Combined Military Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of citicoline in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by Combined Military Hospital. Primary endpoint: Survival in newborn babies with HIE at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
citicoline
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06522581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522581.